Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Eva Hafner"'
Autor:
Jakob Kljun, Renata Pavlič, Eva Hafner, Tanja Lipec, Sara Moreno-Da Silva, Primož Tič, Iztok Turel, Tomaž Büdefeld, Jure Stojan, Tea Lanišnik Rižner
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
In this study, we present the synthesis, kinetic studies of inhibitory activity toward aldo-keto reductase 1C (AKR1C) enzymes, and anticancer potential toward chemoresistant ovarian cancer of 10 organoruthenium compounds bearing diketonate (1–6) an
Externí odkaz:
https://doaj.org/article/f20c38b2a3054eb28ff3e7533d899f2f
Autor:
Renata Pavlič, Marija Gjorgoska, Eva Hafner, Maša Sinreih, Kristina Gajser, Stefan Poschner, Walter Jäger, Tea Lanišnik Rižner
Publikováno v:
Frontiers in Molecular Biosciences, Vol 8 (2021)
Endometrial cancer (EC) is the most common gynecological malignancy in resource-abundant countries. The majority of EC cases are estrogen dependent but the mechanisms of estrogen biosynthesis and oxidative metabolism and estrogen action are not compl
Externí odkaz:
https://doaj.org/article/6336b51297f74a35b21700fe0aaeb502
Autor:
Stefan Poschner, Walter Jäger, Tea Lanišnik Rižner, Eva Hafner, Kristina Marton, Marija Gjorgoska, Renata Pavlič, Maša Sinreih
Publikováno v:
Endometrial cancer.
Introduction/Background* Endometrial cancer (EC) is the most common gynecological malignancy in the western world. EC has traditionally been divided into type I, which is estrogen dependent, and type II, where associations with estrogens were only re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::128c49a9a9a6c5e5bb9f55fc368736fc
https://doi.org/10.1136/ijgc-2021-esgo.196
https://doi.org/10.1136/ijgc-2021-esgo.196
Autor:
Špela Smrkolj, A Adamiak-Godlewska, Simone Ferrero, Jaak Vilo, Vít Weinberger, C Lowy, Fabio Barra, Dmytro Fishman, T. Lanišnik Rižner, Petra Vinklerová, A Semczuk, Eva Hafner, Andrea Romano, Iztok Takač, S Wawrysiuk, C Schröder, Janina Tokarz, Hmj Werner, Markéta Bednaříková, Jure Knez
Publikováno v:
Endometrial cancer.
Introduction/Background* Endometrial cancer is the second most common carcinoma of the female genital tract globally, and its incidence is still increasing. Optimal treatment of EC depends on early diagnostics and pre-operative stratification to appr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a541d5513e5a0b2dd4330cdbf13ce44c
https://doi.org/10.1136/ijgc-2021-esgo.141
https://doi.org/10.1136/ijgc-2021-esgo.141
Autor:
Špela Smrkolj, Eva Hafner, Janina Tokarz, Henrica M J Werner, Aleksandra Kaminska, Vít Weinberger, Aneta Adamiak-Godlewska, Camille Lowy, Christoph Schröder, Iztok Takač, Markéta Bednaříková, Fabio Barra, Tea Lanišnik Rižner, Jaak Vilo, Andrzej Semczuk, Andrea Romano, Dmytro Fishman, Jure Knez, Jerzy Adamski, Petra Vinklerová, Simone Ferrero
Publikováno v:
Cancer Research. 81:464-464
Introduction/Background. Endometrial carcinoma (EC) is the most frequent gynecological malignancy in the developed world. Currently there are no valid non-invasive diagnostic or prognostic methods available and therefore, diagnosis and treatment of E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64e8c8998ace1be5ec5eaec619208e95
https://doi.org/10.1158/1538-7445.am2021-464
https://doi.org/10.1158/1538-7445.am2021-464